Abbott’s Mark Kontny joins Patheon
pharmafile | May 6, 2010 | Appointment | Manufacturing and Production | Patheon, appointment, manufacturing and production
Patheon has appointed Dr Mark Kontny president of global pharmaceutical development services and chief scientific officer.
He joins the contract development and manufacturing services company from Abbott Laboratories, where he was divisional vice president, global pharmaceutical and analytical sciences for their global pharmaceutical research and development organisation.
Patheon’s chief executive and president Wes Wheeler said: “Mark has developed a well deserved reputation for combining strong technical abilities with excellent leadership skills. We look forward to him quickly integrating into the Patheon leadership team and helping us drive our PDS business to an even higher performance level.”
Kontny has spent 25 years in the industry, taking on increasing responsibilities at Ventaira Pharmaceuticals, Boehringer-Ingelheim, Monsanto-G.D. Searle, Pharmacia and Pfizer.
His predecessor Dr Doug Mendenhall steps down as interim president of Patheon’s PDS business and chief scientific officer, but will continue with the company on a part-time basis providing advice and assistance.
Related Content

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …






